Kodu・Aktsiate loetelu・Merck & Co Inc.

Merck & Co Inc.

Suletud

SektorTervishoid

130.3 -0.41

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

129.69

Max

132.76

Põhinäitajad
By Trading Economics
Sissetulek	-7.2B -4.2B
Müük	-114M 16B
P/E Sektori keskmine	35.992 68.51
Aktsiakasum	-1.28
Dividenditootlus	2.52
Kasumimarginaal	-26.053
Töötajad	73,000
EBITDA	-6.4B -2B

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+6.13% upside

Dividendid
By Acuity
Dividenditootlus Sektori keskmine	2.52% 2.29%
Järgmine tulemuste avaldamine	29. okt 2026
Järgmine dividendimakse kuupäev	7. okt 2026
Järgmine aktsia dividendi kuupäev (ex-date)	15. sept 2026

Turustatistika
By TradingEconomics
Turukapital	35B 307B
Eelmine avamishind	130.71
Eelmine sulgemishind	130.3

Uudiste sentiment

By Acuity

52%

48%

247 / 340 Pingereas Healthcare

Merck & Co Inc. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. aug 2026, 19:36 UTC

Social Media

News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7. aug 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6. aug 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5. aug 2026, 19:43 UTC

News

Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4. aug 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3. aug 2026, 20:03 UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31. juuli 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30. juuli 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29. juuli 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28. juuli 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27. juuli 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24. juuli 2026, 18:56 UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22. juuli 2026, 19:46 UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21. juuli 2026, 19:56 UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20. juuli 2026, 20:02 UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Võrdlus sarnastega

Hinnamuutus

Merck & Co Inc. Prognoos

Hinnasiht

By TipRanks

6.13% tõus

12 kuu keskmine prognoos

Keskmine 138.94 USD 6.13%

Kõrge 155 USD

Madal 100 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Merck & Co Inc. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Merck & Co Inc. aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

247 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.